Streetbeat News

Analyst Ratings

CON

B of A Securities has downgraded Concentra Group Holdings from Buy to Neutral and lowered its price target from $30.5 to $24.

Portfolio Pulse from Benzinga Newsdesk

October 07, 2024 | 11:38 am

USPH

B of A Securities has downgraded US Physical Therapy (NYSE:USPH) from Buy to Neutral and reduced the price target from $114 to $90.

Portfolio Pulse from Benzinga Newsdesk

October 07, 2024 | 11:35 am

DOCS

B of A Securities has maintained a Neutral rating on Doximity (NYSE:DOCS) while raising the price target from $32 to $45, indicating a more optimistic outlook on the stock's potential value.

Portfolio Pulse from Benzinga Newsdesk

October 07, 2024 | 11:33 am

PDD

Macquarie analyst Ellie Jiang has upgraded PDD Holdings from Neutral to Outperform and increased the price target from $126 to $224.

Portfolio Pulse from Benzinga Newsdesk

October 07, 2024 | 11:32 am

BABA

Macquarie analyst Ellie Jiang has upgraded Alibaba Group Holdings (NYSE:BABA) from Neutral to Outperform, indicating a positive outlook for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

October 07, 2024 | 11:25 am

AIT

B of A Securities has initiated coverage on Applied Industrial Technologies (AIT) with a Neutral rating and set a price target of $232.

Portfolio Pulse from Benzinga Newsdesk

October 07, 2024 | 11:20 am

ABBV

GILD

GSK

The article highlights three high-dividend yielding healthcare stocks: Gilead Sciences, GSK, and AbbVie. Analysts have provided ratings and price targets for these stocks, with recent news impacting each. Gilead has a licensing agreement with Dr. Reddy's, GSK received U.S. government funding for bird flu vaccines, and AbbVie is set to announce its Q3 financial results.

Portfolio Pulse from Avi Kapoor

October 07, 2024 | 11:19 am

FAST

B of A Securities has initiated coverage on Fastenal with a Buy rating and set a price target of $85.

Portfolio Pulse from Benzinga Newsdesk

October 07, 2024 | 11:18 am

GWW

B of A Securities has initiated coverage on W.W. Grainger with an Underperform rating and set a price target of $925.

Portfolio Pulse from Benzinga Newsdesk

October 07, 2024 | 11:16 am

CMA

B of A Securities has downgraded Comerica (NYSE:CMA) from Neutral to Underperform and reduced its price target from $55 to $52.

Portfolio Pulse from Benzinga Newsdesk

October 07, 2024 | 11:13 am